Economic burden of asthma in Korea

Yo Han Lee, Seok-Jun Yoon, Eun Jung Kim, Young Ae Kim, Hye Young Seo, In Hwan Oh

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Understanding the magnitude of the economic impact of an illness on society is fundamental to planning and implementing relevant policies. South Korea operates a compulsory universal health insurance system providing favorable conditions for evaluating the nationwide economic burden of illnesses. The aim of this study was to estimate the economic costs of asthma imposed on Korean society. The Korean National Health Insurance claims database was used for determining the health care services provided to asthma patients defined as having at least one inpatient or outpatient claim(s) with a primary diagnosis of asthma in 2008. Both direct and indirect costs were included. Direct costs were those associated directly with treatment, medication, and transportation. Indirect costs were assessed in terms of the loss of productivity in asthma patients and their caregivers and consisted of morbidity cost, mortality cost, and caregivers' time cost. The estimated cost for 2,273,290 asthma patients in 2008 was $831 million, with an average per capita cost of $336. Among the cost components, outpatient and medication costs represented the largest cost burden. Although the costs for children accounted for the largest proportion of the total cost, the per capita cost was highest among patients ≥50 years old. The economic burden of asthma in Korea is considerable. Considering that the burden will increase with the rising prevalence, implementation of effective national prevention approaches aimed at the appropriate target populations is imperative.

Original languageEnglish
JournalAllergy and Asthma Proceedings
Volume32
Issue number6
DOIs
Publication statusPublished - 2011 Nov 1

Fingerprint

Korea
Asthma
Economics
Costs and Cost Analysis
Caregivers
Outpatients
Republic of Korea
Cost of Illness
Health Services Needs and Demand
National Health Programs
Health Insurance
Health Services
Inpatients

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Lee, Y. H., Yoon, S-J., Kim, E. J., Kim, Y. A., Seo, H. Y., & Oh, I. H. (2011). Economic burden of asthma in Korea. Allergy and Asthma Proceedings, 32(6). https://doi.org/10.2500/aap.2011.32.3479

Economic burden of asthma in Korea. / Lee, Yo Han; Yoon, Seok-Jun; Kim, Eun Jung; Kim, Young Ae; Seo, Hye Young; Oh, In Hwan.

In: Allergy and Asthma Proceedings, Vol. 32, No. 6, 01.11.2011.

Research output: Contribution to journalArticle

Lee, Yo Han ; Yoon, Seok-Jun ; Kim, Eun Jung ; Kim, Young Ae ; Seo, Hye Young ; Oh, In Hwan. / Economic burden of asthma in Korea. In: Allergy and Asthma Proceedings. 2011 ; Vol. 32, No. 6.
@article{3868bbc0a39d47f0927c8922f20e4399,
title = "Economic burden of asthma in Korea",
abstract = "Understanding the magnitude of the economic impact of an illness on society is fundamental to planning and implementing relevant policies. South Korea operates a compulsory universal health insurance system providing favorable conditions for evaluating the nationwide economic burden of illnesses. The aim of this study was to estimate the economic costs of asthma imposed on Korean society. The Korean National Health Insurance claims database was used for determining the health care services provided to asthma patients defined as having at least one inpatient or outpatient claim(s) with a primary diagnosis of asthma in 2008. Both direct and indirect costs were included. Direct costs were those associated directly with treatment, medication, and transportation. Indirect costs were assessed in terms of the loss of productivity in asthma patients and their caregivers and consisted of morbidity cost, mortality cost, and caregivers' time cost. The estimated cost for 2,273,290 asthma patients in 2008 was $831 million, with an average per capita cost of $336. Among the cost components, outpatient and medication costs represented the largest cost burden. Although the costs for children accounted for the largest proportion of the total cost, the per capita cost was highest among patients ≥50 years old. The economic burden of asthma in Korea is considerable. Considering that the burden will increase with the rising prevalence, implementation of effective national prevention approaches aimed at the appropriate target populations is imperative.",
author = "Lee, {Yo Han} and Seok-Jun Yoon and Kim, {Eun Jung} and Kim, {Young Ae} and Seo, {Hye Young} and Oh, {In Hwan}",
year = "2011",
month = "11",
day = "1",
doi = "10.2500/aap.2011.32.3479",
language = "English",
volume = "32",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Economic burden of asthma in Korea

AU - Lee, Yo Han

AU - Yoon, Seok-Jun

AU - Kim, Eun Jung

AU - Kim, Young Ae

AU - Seo, Hye Young

AU - Oh, In Hwan

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Understanding the magnitude of the economic impact of an illness on society is fundamental to planning and implementing relevant policies. South Korea operates a compulsory universal health insurance system providing favorable conditions for evaluating the nationwide economic burden of illnesses. The aim of this study was to estimate the economic costs of asthma imposed on Korean society. The Korean National Health Insurance claims database was used for determining the health care services provided to asthma patients defined as having at least one inpatient or outpatient claim(s) with a primary diagnosis of asthma in 2008. Both direct and indirect costs were included. Direct costs were those associated directly with treatment, medication, and transportation. Indirect costs were assessed in terms of the loss of productivity in asthma patients and their caregivers and consisted of morbidity cost, mortality cost, and caregivers' time cost. The estimated cost for 2,273,290 asthma patients in 2008 was $831 million, with an average per capita cost of $336. Among the cost components, outpatient and medication costs represented the largest cost burden. Although the costs for children accounted for the largest proportion of the total cost, the per capita cost was highest among patients ≥50 years old. The economic burden of asthma in Korea is considerable. Considering that the burden will increase with the rising prevalence, implementation of effective national prevention approaches aimed at the appropriate target populations is imperative.

AB - Understanding the magnitude of the economic impact of an illness on society is fundamental to planning and implementing relevant policies. South Korea operates a compulsory universal health insurance system providing favorable conditions for evaluating the nationwide economic burden of illnesses. The aim of this study was to estimate the economic costs of asthma imposed on Korean society. The Korean National Health Insurance claims database was used for determining the health care services provided to asthma patients defined as having at least one inpatient or outpatient claim(s) with a primary diagnosis of asthma in 2008. Both direct and indirect costs were included. Direct costs were those associated directly with treatment, medication, and transportation. Indirect costs were assessed in terms of the loss of productivity in asthma patients and their caregivers and consisted of morbidity cost, mortality cost, and caregivers' time cost. The estimated cost for 2,273,290 asthma patients in 2008 was $831 million, with an average per capita cost of $336. Among the cost components, outpatient and medication costs represented the largest cost burden. Although the costs for children accounted for the largest proportion of the total cost, the per capita cost was highest among patients ≥50 years old. The economic burden of asthma in Korea is considerable. Considering that the burden will increase with the rising prevalence, implementation of effective national prevention approaches aimed at the appropriate target populations is imperative.

UR - http://www.scopus.com/inward/record.url?scp=84355167672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84355167672&partnerID=8YFLogxK

U2 - 10.2500/aap.2011.32.3479

DO - 10.2500/aap.2011.32.3479

M3 - Article

VL - 32

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 6

ER -